secwatch.observer — SEC 8-K summary
======================================

Issuer:     Scorpius Holdings, Inc. (—)
CIK:        0001476963
Form:       8-K
Filed at:   2023-12-27T23:59:59+00:00
Accession:  0001079973-23-001821
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.01, 2.03, 1.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NightHawk Biosciences sells Elusys Therapeutics to entity controlled by CEO Jeffrey Wolf
--------------------------------------------------------------------------------

- Sale of all equity of Elusys Therapeutics for $500K upfront plus 3% royalty on ANTHIM sales through 2031 (min $5M guarantee).
- Buyer assumes ~$40M in liabilities and manufacturing commitments from Elusys.
- Buyer obligated to purchase $2.25M convertible note (1% interest, 1-yr maturity) convertible into ~5.7M shares at $0.39281/sh.
- Transaction is with a related party: Buyer controlled by CEO Jeffrey Wolf; Wolf and CFO Ostrander continue with both companies.
- NightHawk enters shared services agreement for transitional support; fees based on cost recovery.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1476963/000107997323001821/0001079973-23-001821-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1476963/000107997323001821/nhwk_8k.htm
  HTML page:      https://secwatch.observer/filing/0001079973-23-001821

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer